Cimzia Approval History

Cimzia (certolizumab) is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of Crohn’s disease, rheumatoid arthritis and psoriatic arthritis in adults.

FDA Approval History for Cimzia

DateArticle
Oct 18, 2013Approval Cimzia Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Sep 30, 2013Approval FDA Approves Cimzia for Treatment of Adult Patients with Active Psoriatic Arthritis
Jul 24, 2013U.S. FDA Arthritis Advisory Committee Votes On Cimzia (certolizumab pegol) For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis
May 13, 2009Approval UCB's Cimzia (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Feb  6, 2009UCB's meeting with U.S. FDA defines path forward for Cimzia in rheumatoid arthritis
Jan  5, 2009UCB Receives Complete Response Letter from U.S. FDA for Use of Cimzia in Rheumatoid Arthritis Patients
Apr 22, 2008Approval Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Feb  6, 2008FDA Agrees to Review Cimzia File for the Treatment of Rheumatoid Arthritis
Mar 23, 2007UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid Arthritis in the US
Mar  2, 2006UCB Submits Biologics License Application to FDA for New Treatment in Crohn's Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)